Abstract
Vasopressin antagonists1–7 are valuable pharmacological tools for investigating physiological and behavioural functions of the nonapeptide arginine-vasopressin (AVP)8,9. The removal of glycinamide from the carboxy terminus of AVP drastically reduces its characteristic vasopressor and antidiuretic activities10. In contrast to this we show here that removal of the carboxy-terminal glycinamide or the glycine at position 9 from several vasopressin antagonists makes little difference to their ability to block vasopressor and antidiuretic responses to AVP. These data demonstrate the critical structural requirements of the carboxy-terminal position for receptor activation, in contrast to the lack of such requirements for receptor binding. They also provide an avenue to a wide variety of antagonists substituted at the carboxy terminus (for example radiolabelled derivatives and affinity ligands) and suggest clues for the development of more potent and/or selective antagonists.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sawyer, W. H., Grzonka, Z. & Manning, M. Molec. cell. Endocr. 22, 117–134 (1981).
Kruszynski, M. et al. J. med. Chem. 25, 364–368 (1980).
Sawyer, W. H. et al. Science 212, 49–51 (1981).
Manning, M., Lammek, B., Kolodziejczyk, A. M., Seto, J. & Sawyer, W. H. J. med. Chem. 24, 701–706 (1981).
Manning, M. et al. J. med. Chem. 25, 45–50 (1982(a)).
Manning, M., Klis, W. A., Olma, A., Seto, J. & Sawyer, W. H. J. med. Chem. 25, 414–419 (1982).
Manning, M., Olma, A., Klis, W. A., Seto, J. & Sawyer, W. H. J. med. Chem. 26, 1607–1613 (1983).
Reid, I. A. & Schwartz, J. in Frontiers in Neuroendocrinology Vol. 8 (eds Martini, L. & Ganong, W. F.) 177–197 (Raven, New York, 1984).
Manning, M. & Sawyer, W. H. Trends Neurosci. 7, 6–9 (1984).
du Vigneaud, V., Lawler, H. C. & Popenoe, E. A. J. Am. chem. Soc. 75, 4880–4881 (1953).
Kovacs, G. L. & de Wied, D. Neuroendocrinology 37, 258–261 (1983).
Burbach, J. P. H., Kovacs, G. L., de Wied, D., van Nispen, J. W. & Greven, H. M. Science 221, 1310 (1983).
Dousa, T., Hechter, O., Walter, R. & Schwartz, I. L. Science 167, 1134–1135 (1970).
Sawyer, W. H. Endocrinology 63, 694–698 (1958).
Dekanski, J. Br. J. Pharmac. 7, 567–572 (1952).
Dyckes, D. F., Nestor, J. J. Jr, Ferger, M. F. & du Vigneaud, V. J. med. Chem. 17, 250–252 (1974).
Schild, H. O. Br. J. Pharmac. chem. Ther. 2, 189–206 (1947).
Barany, G. & Merrifield, R. B. in The Peptides Vol. 2 (eds Gross, E. & Meienhofer, J.) 1–284 (Academic, New York, 1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Manning, M., Olma, A., Klis, W. et al. Carboxy terminus of vasopressin required for activity but not binding. Nature 308, 652–653 (1984). https://doi.org/10.1038/308652a0
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1038/308652a0
This article is cited by
-
A Self-Assembling Lipidic Peptide and Selective Partial V2 Receptor Agonist Inhibits Urine Production
Scientific Reports (2020)
-
Peptidylglycine α-amidating monooxygenase activity and TRH and CRF biosynthesis
Biological Trace Element Research (1992)
-
Autoradiographic localization of vasopressin and oxytocin binding sites in rat kidney
Kidney International (1988)
-
Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure
Kidney International (1986)
